🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 39 of 116

  1. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Myeloid Neoplasm

    phase 2 small molecule active

    1 trial

  2. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Leukemia, Myeloid, Acute

    phase 2 small molecule completed

    1 trial

  3. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Lymphoid Leukemia

    phase 2 small molecule completed

    1 trial

  4. CR-001

    CRESCENT BIOPHARMA, INC.

    Locally Advanced / Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  5. CRB-601 monoclonal antibody

    Corbus Pharmaceuticals Holdings

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. CRB-701

    Corbus Pharmaceuticals Holdings

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  7. CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  8. CRN09682

    Crinetics Pharmaceuticals Europe GmbH

    SST2-positive Neuroendocrine Neoplasms

    phase 2 small molecule active

    1 trial

  9. CS1001

    Cstone Pharmaceuticals Ireland Limited

    Advanced Refractory Solid Tumors

    phase 2 small molecule completed

    1 trial

  10. CT-011

    Teva Pharma GmbH

    Primary Hepatocellular Carcinoma

    phase 2 small molecule terminated

    1 trial

  11. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Renal Cell Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  12. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  13. CT7001, PF-07850327 round

    Pfizer Australia Pty Ltd

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  14. CTX-009

    Compass Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  15. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  16. CTX112

    S.A.

    B-cell Lymphoma

    phase 2 mab active

    1 trial

  17. CTX131

    S.A.

    T Cell Lymphoma

    phase 2 mab completed

    1 trial

  18. CTX131

    S.A.

    Clear Cell Renal Cell Carcinoma

    phase 2 mab completed

    1 trial

  19. CUE-101

    Cue Biopharma

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. CUE-101

    Cue Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  21. CX-072

    CytomX Therapeutics

    Solid Tumor

    phase 2 small molecule terminated

    2 trials

  22. CX-2009

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule terminated

    1 trial

  23. CX-2009

    CytomX Therapeutics

    Neoplasms

    phase 2 small molecule completed

    1 trial

  24. CX-2029

    CytomX Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  25. CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE

    Celgene Europe Limited

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  26. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  27. CYTARABINE , LONCASTUXIMAB TESIRINE, RITUXIMAB, BENDAMUSTINE

    Fondazione Telethon ETS

    Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  28. CYTARABINE, METHYLPREDNISOLONE, Iclusig 15 mg film-coated tablets, METHOTREXATE, VINCRISTINE, PONATINIB, PREDNISONE

    Fondazione Telethon ETS

    Ph+ Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  29. CYTARABINE, SULFASALAZINE, IDARUBICIN HYDROCHLORIDE

    Pari Pharma GmbH

    Recently diagnosed non favorable Acute Myeloid Leukemias

    phase 2 small molecule active

    1 trial

  30. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  31. Cabozantinib

    Takeda

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  32. Cabozantinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  33. Cabozantinib

    Takeda

    Advanced Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  34. Cadonilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  35. Cadonilimab

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  36. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  37. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  38. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, TRABECTEDIN

    Fondazione Telethon ETS

    recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  39. Calcio levofolinato Teva Generics 175 mg polvere per soluzione per infusione, BEVACIZUMAB , ZALTRAP 25 mg/ml concentrate for solution for infusion, Oxaliplatin 5 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, FLUOROURACIL , FLUOROURACIL , Irinotecan Accord 20 mg/ml concentrato per soluzione per infusione, CAPECITABINE

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial

  40. Calciumfolinat HEXAL 10 mg/ml Injektionslösung, Irinotecan HCl AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BNT321, FLUOROURACIL, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech SE

    Resected (R0 or R1) pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  41. Calquence 100 mg film-coated tablets

    AstraZeneca

    mantle cell lymphoma (MCL)

    phase 2 small molecule active

    1 trial

  42. Calquence 100 mg film-coated tablets, ACALABRUTINIB

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  43. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  44. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  45. Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  46. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  47. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  48. Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DEXAMETHASONE , Temodal 180 mg hard capsules, Temodal 5 mg hard capsules, Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Temodal 20 mg hard capsules, Temodal 250 mg hard capsules

    Inhibrx Biosciences

    Advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.